Promoter CpG methylation of multiple genes in pituitary adenomas: Frequent involvement of Caspase-8

Oncology Reports

Volumn 15, Issue 2, 2006, Pages 443-448

  Bello, M Josefa ^a   De Campos, Jose M ^b   Isla, Alberto ^a   Casartelli, Cacilda ^c   Rey, Juan A ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Caspase 8; CpG island; Pituitary adenomas; Promoter hypermethylation

Indexed keywords

CASP8 PROTEIN, HUMAN; CASPASE; CASPASE 8;

ADENOMA; ADULT; AGE; AGED; ARTICLE; CPG ISLAND; DNA METHYLATION; FEMALE; GENETIC EPIGENESIS; GENETICS; HUMAN; HYPOPHYSIS TUMOR; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGION; SEX DIFFERENCE; TUMOR GENE;

ADENOMA; ADULT; AGE FACTORS; AGED; CASPASE 8; CASPASES; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); SEX FACTORS;

EID: 33744468012     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.2.443     Document Type: Article

References (36)

1. Shimon I and Melmed S: Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocr Metab 82: 1675-1681, 1997.
2. Assa SL and Ezzat SZ: The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 19: 798-827, 1998.
3. Finelli P, Giardino D, Rizzi N, Buiatiotis S, Virduci T, Franzin A, Losa M and Larizza L: Non-random trisomies of chromosomes 5, 8 and 12 in the prolactinoma sub-type of pituitary adenomas: conventional cytogenetics and interphase FISH study. Int J Cancer 86: 344-350, 2000. (Pubitemid 30187494)
4. Bello MJ, de Campos JM, Kusak ME, Vaquero J, Sarasa JL and Rey JA: Chromosomal abnormalities in pituitary adenomas. Cancer Genet Cytogenet 124: 76-79, 2001. (Pubitemid 32101474)
5. Fan X, Paetau A, Aalto Y, Valimaki M, Sane T, Porenen A, Castresana JS and Knuutila S: Gain of chromosome 3 and loss of 13q are frequent alterations in pituitary adenomas. Cancer Genet Cytogenet 128: 97-103, 2001. (Pubitemid 32706580)
6. Trautmann K, Thakker RV, Ellison DW, Ibrahim A, Lees PD, Harding B, Fischer C, Popp S, Bartram CR and Jauch A: Chromosomal aberrations in sporadic pituitary tumors. Int J Cancer 91: 809-814, 2001. (Pubitemid 32178649)
7. Simpson DJ, Bicknell EJ, Buch HN, Cutty SJ, Clayton RN and Farrel WE: Genome-wide amplification and allelotyping of sporadic adenomas identify novel regions of genetic loss. Genes Chromosomes Cancer 37: 225-236, 2003. (Pubitemid 36667561)
8. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR and Valar L: GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylate cyclase in human pituitary tumors. Nature 340: 566-568, 1989.
9. Zhuang Z, Ezzat SZ, Vortmeyer AO, Weil R, Oldfield EH, Park W-S, Pack S, Huang S, Agarwal SK, Guru SC, Manickam P, Debelenko LV, Kester MB, Olufemi S-E, Heppener C, Crabtree JS, Burns AL, Spiegel AM, Marx SJ, Chandrasekharappa SC, Collins FS, Emmert-Buck MR, Liotta IA, Asa SL and Lubensky IA: Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res 57: 5446-5451, 1997. (Pubitemid 28006744)
10. Zhang X, Horwitz GA, Heaney AP, Nakamura M, Prezant TR, Bronstein MD and Melemd S: Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84: 761-767, 1999. (Pubitemid 29075718)
11. Simpson DJ, Magnay J, Bicknell JE, Barkan AL, McNicol AM, Clayton RN and Farrell WE: Chromosome 13q deletion mapping in pituitary tumors: infrequent loss of the retinoblastoma susceptibility gene (RB1) locus despite of RB1 protein product in somatotrophinomas. Cancer Res 59: 1562-1566, 1999. (Pubitemid 29160126)
12. Woloschak M, Yu A, Xiao J and Post KD: Frequent loss of P16INK4a gene product in human pituitary tumors. Cancer Res 56: 2493-2496, 1996.
13. Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS and Clayton RN: Chromosome 9p deletions in invasive and non-invasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res 57: 2703-2709, 1997. (Pubitemid 27283783)
14. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP: Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72: 141-196, 1998. (Pubitemid 27435555)
15. Esteller M, Corn PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res 61: 3225-3229, 2001. (Pubitemid 32695003)
16. Farrell WE and Clayton RN: Epigenetic change in pituitary tumorigenesis. Endocr-Relat Cancer 10: 323-330, 2003. (Pubitemid 36758658)
17. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN and Farrell WF: Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 60: 1211-1216, 2000. (Pubitemid 30151985)
18. Simpson DJ, Bicnell JE, McNicol AM, Clayton RN and Farrell WE: Hypermethylation of the p16/CDKN2A/MTS1 gene and loss of protein expression is associated with non-functional pituitary adenomas but not somatotrophinomas. Genes Chromosomes Cancer 24: 328-336, 1999. (Pubitemid 29115871)
19. Ruebel KH, Jin L, Zhang S, Scheitauer BW and Lloyd RV: Inactivation of the p16 gene in human pituitary non-functional tumors by hypermethylation is more common in null cell adenomas. Endocr Pathol 12: 281-289, 2001. (Pubitemid 34066749)
20. Seemann N, Kuhn D, Wrocklage C, Keyvani K, Hackl W, Buchfelder M, Fahlbusch R and Paulus W: CDKN2A/p16 inactivation is related to pituitary adenoma type and size. J Pathol 193: 491-497, 2001. (Pubitemid 32266818)
21. Ogino A, Yoshino A, Katayama Y, Watanabe T, Ota T, Komine C, Yokoyama T and Fukushima T: The p15INK4b/p16INK4a/RB1 pathway is frequently deregulated in human pituitary adenomas. J Neuropathol Exp Neurol 64: 398-403, 2005. (Pubitemid 40629130)
22. Simpson DJ, Clayton RN and Farrell WE: Preferential loss of Death Associated Protein Kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion. Oncogene 21: 1217-1224, 2002. (Pubitemid 34185238)
23. Qian ZR, Sano T, Yoshimoto K, Yamada S, Ishizuka A, Mizusawa N, Horiguchi H, Hirokawa M and Asa SL: Inactivation of RASSF1A tumour-suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. Lab Invest 85: 464-473, 2005. (Pubitemid 40523939)
24. Rey JA, Bello MJ, Jimenez-Lara A, Vaquero J, Kusak ME, de Campos JM, Sarasa JL and Pestaña A: Loss of heterozygosity for distal markers on 22q in human gliomas. Int J Cancer 51: 703-706, 1992.
25. Herman JG, Graff JR, Myohannen S, Nelkin BD and Baylin SB: Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
26. Gonzalez-Gomez P, Bello MJ, Lomas J, Arjona D, Alonso ME, Amiñoso C, Lopez-Marin I, Anselmo NP, Sarasa JL, Gutierrez M, Casartelli C and Rey JA: Aberrant methylation of multiple genes in neuroblastic tumours: relationship with MYCN amplification and allelic status at 1p. Eur J Cancer 39: 1478-1485, 2003. (Pubitemid 36773792)
27. Yoshimoto K, Tanaka C, Yanmada S, Kimura T, Iwahana H, Sano T and Itakura M: Infrequent mutations of p16INK4A and p15INK4B genes in human pituitary tumors. Eur J Endocrinol 136: 74-80, 1997.
28. Woloschak M, Yu A and Post KD: Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol Carcinog 19: 221-224, 1997. (Pubitemid 27391999)
29. Jaffrain-Rea ML, Ferretti F, Toniato E, Cannita K, Santoro A, di Stefano D, Ricevuto E, Maroder M, Tamburrano G, Cantore G, Gulino A and Martinotti S: p16(INK4a, MTS-1) gene polymorphism and methylation status in human pituitary tumours. Clin Endocrinol 51: 317-325, 1999. (Pubitemid 29439051)
30. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF and Sher CJ: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95: 8292-8297, 1998. (Pubitemid 28326106)
31. Tada M, Kobayashi H and Moriuchi T: Molecular basis of pituitary oncogenesis. J Neuro-Oncol 45: 83-96, 1999. (Pubitemid 30142444)
32. Bahar A, Simpson DJ, Cutty SJ, Bicknell JE, Hoban PR, Holley S, Mourtada-Maarabouni M, Williams GT, Clayton RN and Farrell WE: Isolation and characterization of a novel pituitary tumor apoptosis gene. Mol Endocrinol 18: 1827-1839, 2004. (Pubitemid 38859588)
33. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J and Tschopp J: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2: 241-243, 2000.
34. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM and Kidd VJ: Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 6: 529-535, 2000. (Pubitemid 30305902)
35. Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Philips PC, Shalaby T and Grotzer MA: Loss of Caspase-8 protein expression correlates with unfavorable survival outcome in childhood medulloblastoma. Clin Cancer Res 9: 6401-6409, 2003. (Pubitemid 38031826)
36. Gonzalez-Gomez P, Bello MJ, Inda MM, Alonso ME, Arjona D, Amiñoso C, Lopez-Marin I, de Campos JM, Sarasa JL, Castresana JS and Rey JA: Deletion and aberrant CpG island methylation of Caspase 8 gene in medulloblastoma. Oncol Rep 12: 663-666, 2004.